seeking biotech alpha July 2019 & October 2018 insight

TECENTRIQ (atezolizumab) plus ABRAXANE (nab-paclitaxel)

image19

 Roche's Tecentriq extends progression-free survival in first-line TNBC

 Results from a Phase 3 clinical trial, IMpassion130, evaluating Roche (OTCQX:RHHBY) unit Genentech's TECENTRIQ (atezolizumab) plus Celgene's (NASDAQ:CELG) ABRAXANE (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) showed a treatment effect. The data were presented at ESMO in Munich. 

Oct. 20, 2018 7:28 PM ET|By: , SA News Edito 


TECENTRIQ is a prescription medicine used to treat: A type of bladder and urinary tract cancer called urothelial carcinoma. And -A type of lung cancer called non-small cell lung cancer (NSCLC)

KEYTRUDA® (pembrolizumab)

image20

  Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)

Mon July 29, 2019 6:55 AM|Business Wire|About: MRK 


 https://www.businesswire.com/news/home/20190729005182/en/ 

KEYTRUDA is not chemotherapy or radiation therapy—it is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work.

Opdivo (nivolumab) + Yervoy (ipilimumab)

image21

 Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study

Oct. 20, 2018 6:09 PM ET|By: , SA News Editor 

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib)

image23

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

Mon July 29, 2019 6:30 AM|Business Wire|About: MRK

Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

INLYTA is a prescription medicine used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC) when one prior drug treatment regimen for your RCC has not worked.

IBRANCE (palbociclib) and FASLODEX (fulvestrant)

image24

 Ibrance + Faslodex extends survival in late-stage breast cancer study

Oct. 20, 2018 6:21 PM ET|By: , SA News Editor 

 Pfizer (NYSE:PFE) announces overall survival (OS) data from the Phase 3 PALOMA-3 trial evaluating the combination of IBRANCE (palbociclib) and AstraZeneca's (NYSE:AZN) FASLODEX (fulvestrant) in women with HR+/HER2- metastatic breast cancer who progressed on or after prior endocrine therapy, an indication approved in the U.S. in March. 

IBRANCE® (palbociclib) is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.

seeking biotech alpha July 2019 & October 2018 insight

OPDIVO® (nivolumab) + YERVOY® (ipilimumab)

image27

 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  • CATEGORY: 

CORPORATE/FINANCIAL NEWSMONDAY, OCTOBER 22, 2018 

6:45 AM EDT 

 PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY)  

OPDIVO is a medicine that may treat certain cancers by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work

LOKELMA™ (sodium zirconium cyclosilicate)

image28

 AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

Mon October 22, 2018 7:00 AM|Business Wire|About: AZN 

LOKELMA is indicated for the treatment of hyperkalemia in adults. NOW FDA-APPROVED

RECARBRIO™ (imipenem, cilastatin, and relebactam)

image29

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available

Wed July 17, 2019 6:45 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK),

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available Wednesday, July 17, 2019 6:45 am EDT

AzymetricTM platform

image30

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

Tue July 16, 2019 8:30 AM|Business Wire|About: ZYME

  • First of ten potential products built on Zymeworks’ proprietary AzymetricTMplatform
  • Zymeworks (ZYME) to receive US$7.5 million commercial license payment

VANCOUVER, British Columbia--(BUSINESS WIRE)


 https://www.businesswire.com/news/home/20190716005225/en/ 

Our proprietary platforms: Azymetric™, ZymeLink™, and EFECT™ can be easily used in combination with each other and with existing approaches without compromising manufacturability. Our platforms enables the development next-generation biotherapeutics to result in superior patient outcomes.

seeking biotech alpha July 2019 insight

MitraClip™ heart valve repair device

image31

Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform

Mon July 15, 2019 12:46 PM|PR 

Newswire|About: ABT

- G4 includes new clip sizes and an enhanced leaflet grasping feature

PR Newswire

ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (ABT)

EXPLORE THE ABBOTT PORTFOLIO OF STRUCTURAL HEART SOLUTIONS

Intuitive (ISRG)

image32

 Intuitive Surgical acquires Schölly Fiberoptic’s robotic endoscope business

Mon July 15, 2019 4:15 PM|GlobeNewswire|About: ISRG

SUNNYVALE, Calif. and DENZLINGEN, Germany, July 15, 2019 (GLOBE NEWSWIRE) -- Intuitive (ISRG)

15/07/19 | Company INTUITIVE SURGICAL ÜBERNIMMT DAS ROBOTIK-ENDOSKOPIE-GESCHÄFT VON SCHÖLLY FIBEROPTIC GMBH

Emgality® (galcanezumab-gnlm)

image33

  AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine

Fri July 12, 2019 6:45 AM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY

October 31, 2018 AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia

crizanlizumab (SEG101)

image34

  FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

Jul 16, 2019

  • FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from standard ten months
     
  • Vaso-occlusive crises (also called sickle cell pain crises) are unpredictable and extremely painful events that can lead to serious life-threatening complications and death[1]

Basel, July 16, 2019 -


 https://seekingalpha.com/news/3477970-fda-accepts-novartis-application-sickle-cell-med-crizanlizumab 

Crizanlizumab (SEG101) HOME » CRIZANLIZUMAB (SEG101) Crizanlizumab (SEG101, formerly SelG1) is an anti-P-selectin antibody being developed by Novartis as a potential treatment of sickle cell anemia.

Dovato (dolutegravir Plus Lamivudine)

image35

 ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen

Wed July 10, 2019 2:15 AM|Business Wire|About: GSK, PFE 

DOVATO is a prescription medicine that is used without other antiretroviral medicines to treat human immunodeficiency virus-1 (HIV-1) infection in adults who have not received antiretroviral medicines in the past, and without known resistance to the medicines dolutegravir or lamivudine. HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS)

Gilead Sciences and Renown Institute for Health Innovation

image36

 Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Thu July 11, 2019 8:30 AM|Business Wire|About: GILD

FOSTER CITY, Calif. & RENO, Nev.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and the Renown Institute for Health Innovation (IHI)

Renown is northern Nevada’s healthcare leader and Reno’s only locally owned, not-for-profit health system. We are an entire network of Reno hospitals, urgent care centers, lab services, x-ray and imaging services, primary care doctors and dozens of medical specialties. We help you live a healthier life, and we’re the experts you go to when you are seriously ill or injured. We have more than 6,000 nurses, doctors and care providers dedicated to your health and well-being every day of the year.

seeking biotech alpha July 2019 insight

AbbVie (ABBV) announced today that it has acquired Seattle-based Mavupharma,

image37

 AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Mon July 15, 2019 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ -- AbbVie (ABBV

July 15, 2019 AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Valoctocogene Roxaparvovec

image38

BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe

Mon July 8, 2019 8:01 AM|PR Newswire|About: BMRN

Late-Breaking Abstract at the 27th International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress Presents 3 Years of Efficacy and Safety of Valoctocogene Roxaparvovec

PR Newswire

SAN RAFAEL, Calif., July 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN

Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A Valoctocogene roxaparvovec is gene therapy designed for the treatment of Hemophilia A.

BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) + Eli Lilly's ERBITUX (cetuximab)

image39

 Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

Sat July 6, 2019 5:19 AM|PR Newswire|About: ARRY

- Data supports potential to be the first chemotherapy-free, targeted regimen for BRAF-mutant mCRC patients -

- Results were presented in an oral presentation today, July 6, 2019 -

PR Newswire

BOULDER, Colo., July 6, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY


Array Bio's triplet therapy extends survival in late-stage CRC study

Jul. 8, 2019 7:33 AM ET|About: Array BioPharma Inc. (ARRY)|By: , SA News Editor  

BRAFTOVI and MEKTOVI are prescription medicines used together to treat people with a type of skin cancer called melanoma: that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene

Vascepa® (icosapent ethyl)

image40

 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance

Tue July 2, 2019 6:00 AM|GlobeNewswire|About: AMRN

  • Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa
  • Guidance for Total 2019 Revenue Increased to a Range of $380 to $420 Million from $350 Million Following Unaudited Second Quarter Results Estimated Between $97 and $101 Million, or Between $170 and $174 Million for the First Half of 2019
  • U.S. Sales Force to Double in Size; Recruiting Commenced
  • Vascepa sNDA PDUFA Goal Date On-Track for September 28, 2019; Potential for Therapy to Become First Prescription Product Available for Cardiovascular Risk Reduction in Patients with Elevated Triglyceride Levels, Despite Statin Therapy

BEDMINSTER, N.J. and DUBLIN, Ireland, July 02, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN)

VASCEPA is a prescription medicine used along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults.

XOFLUZA (Baloxavir Marboxil)

image42

 Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu

Wed July 3, 2019 1:00 AM|Business Wire|About: RHHBY 

XOFLUZA is a prescription medicine used to treat the flu (influenza) in people 12 years of age and older who have had flu symptoms for no more than 48 hours.

seeking biotech alpha July 2019 insight

Opicapone

image43

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

Wed July 10, 2019 4:10 PM|PR Newswire|About: NBIX

- Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 26, 2020

Opicapone CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITOR: AN INVESTIGATIONAL TREATMENT FOR PARKINSON’S DISEASE

Alinity™ s System.

image44

Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply

Thu July 11, 2019 9:00 AM|PR Newswire|About: ABTPR Newswire

ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (ABT

ALINITY SYSTEMS AND PATIENT CARE How diagnostic tests serve as a compass for healthcare

KEYTRUDA® (pembrolizumab)

image45

 FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications

Tue July 9, 2019 6:45 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)


 https://www.merck.com/clinical-trials/index.html 

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work.

Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPGF)

image47

 Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

Sun July 14, 2019 1:00 PM|Business Wire|About: GILD, GLPG

– Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment –

– Gilead Gains Access to Galapagos’ Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of Europe –

– Investment Enables Galapagos to Expand and Accelerate Research and Clinical Programs –

– Galapagos Gains Broader Commercialization Role for Filgotinib in Europe and Agrees to Share Equally in Future Development Costs –

– Gilead Agrees to 10-year Standstill –

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPGF)

Gilead to boost Galapagos stake in $5.1B deal Jul. 14, 2019 4:25 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Carl Surran, SA News Editor

ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated)

image48

 ESPEROCT® is now approved in Canada for the Treatment of Hemophilia A in both Children and Adults

Fri July 12, 2019 7:00 AM|Canada Newswire|About: NVO

New treatment can help Canadians living with hemophilia A better manage their bleeding episodes

TORONTO, July 12, 2019 /CNW/ - 

Esperoct®, antihemophilic factor (recombinant), glycopegylated-exei

Seeking biotech alpha July 2019 & October 2018 insight

BMS-986179 With Enhanze®

image49

 Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

Thu October 25, 2018 8:00 AM|PR Newswire|About: BMY, HALO

SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO)

Halozyme’s ENHANZE® drug delivery technology is based on our patented recombinant human hyaluronidase enzyme , rHuPH20 to enable and optimize subcutaneous drug delivery for appropriate co-administered therapies.

Home Hemodialysis Device

image50

CVS Health Announces Start of Clinical Trial for New Home Hemodialysis Device

Wed July 17, 2019 8:00 AM|PR Newswire|About: CVS

Represents next step in company-wide strategy to help improve kidney disease diagnosis and management

PR Newswire

WOONSOCKET, R.I., July 17, 2019 /PRNewswire/ -- CVS Health (CVS)

CVS Health Announces Start of Clinical Trial for New Home Hemodialysis Device Wednesday, July 17, 2019 HemoCare Hemodialysis System designed for home dialysis to enable patients to benefit from longer treatment as compared to in-center treatments Represents next step in company-wide strategy to help improve kidney disease diagnosis and management WOONSOCKET, R.I., July 17, 2019 /PRNewswire/ -- CVS Health (NYSE: CVS)

BAN2401, an anti-amyloid beta protofibril antibody,

image51

 Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Thu October 25, 2018 8:31 AM|GlobeNewswire|About: BIIB

TOKYO and CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States

October 25, 2018 at 8:31 AM EDT TOKYO and CAMBRIDGE, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced that Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease

Influenza A & B 2 and Strep A 2 molecular assays

image53

 Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results

Thu October 25, 2018 9:00 AM|PR Newswire|About: ABTPR Newswire

ABBOTT PARK, Ill., Oct. 25, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) 

Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT

Stivarga® (regorafenib) and Opdivo® (nivolumab)

image54

  Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer

Thu July 18, 2019 6:30 AM|Business Wire|About: BMY

  • Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer
  • Companies plan indication-seeking trial

WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan--(BUSINESS WIRE)-- Bayer, Bristol-Myers Squibb Company (BMY) (NYSE: BMY)

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer Companies plan indication-seeking trial July 18, 2019 06:30 AM Eastern Daylight Time WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan--(BUSINESS WIRE)--Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”

Seeking Biotech Alpha June 2019 Insight

ZIRABEV™ (bevacizumab-bvzr)

image55

 Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

Fri June 28, 2019 7:33 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE)

PFIZER RECEIVES U.S. FDA APPROVAL FOR ITS ONCOLOGY BIOSIMILAR, ZIRABEV™ (BEVACIZUMAB-BVZR) Friday, June 28, 2019 - 7:33am EDT

IMFINZI® (durvalumab)

image56

 IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer

Thu June 27, 2019 8:56 AM|Business Wire|About: AZN

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-

IMFINZI® (durvalumab) is a prescription medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.

SOLIRIS® (eculizumab)

image57

 Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive

Thu June 27, 2019 2:11 PM|Business Wire|About: ALXN

- At 48 weeks, 98% of patients treated with SOLIRIS were relapse free compared to 63% of patients receiving placebo -

- SOLIRIS is the first and only FDA approved treatment for this rare, severe, condition that attacks the central nervous system without warning -

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN

SOLIRIS is a medicine that affects your immune system. SOLIRIS can lower the ability of your immune system to fight infections. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone

image58

 Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible

  • Combination regimen reduced the risk of disease progression or death by 44 percent in newly diagnosed patients who are transplant ineligible
  • Marks the sixth DARZALEX FDA-approved use in multiple myeloma and second for newly diagnosed patients

HORSHAM, Pa., June 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson 

DARZALEX® is now approved in combination with the medicines lenalidomide and dexamethasone for adult patients with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)

Victoza® (liraglutide)

image59

 FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years

PLAINSBORO, N.J., June 17, 2019 /PRNewswire/ -- Novo Nordisk


 Novo Nordisk A/S (NVO)

NVO
$51.04
0.18 0.35%
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide.
52 Week Range
41.23 - 52.83
Market Cap.
120.97B
More »
(30,945 followers)

Victoza® (liraglutide) injection 1.2 mg or 1.8 mg is an injectable prescription medicine for adults with type 2 diabetes that: along with diet and exercise may improve blood sugar (glucose).

seeking biotech alpha July 2019 & October 2018 insight

Bioinformatics Hub

image63

 Intrexon Announces the Formation of Bioinformatics Hub in Munich

Wed October 24, 2018 7:30 AM|PR Newswire|About: XONPR Newswire

GERMANTOWN, Md., Oct. 24, 2018 /PRNewswire/ -- Intrexon Corporation(NASDAQ: XON)

Intrexon Announces the Formation of Bioinformatics Hub in Munich Establishing itself as Intrexon Bioinformatics Germany GmbH (IBG) GERMANTOWN, Md., Oct. 24, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON)

Zanubrutinib

image64

 BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Wed October 24, 2018 7:00 AM|GlobeNewswire|About: BGNE

BEIJING, China, and CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)

ZANUBRUTINIB: AN INVESTIGATIONAL BTK INHIBITOR Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of BTK that is currently being evaluated in a broad pivotal clinical program globally and in China as a monotherapy and in combination with other therapies to treat various lymphomas.

Medtronic SynchroMed™ II pump

image65

 FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain

(GLOBE NEWSWIRE via COMTEX) --myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician

DUBLIN - October 24, 2018 - Medtronic plc (NYSE:MDT)

The Medtronic SynchroMed™ II pump is part of the SynchroMed II programmable drug infusion system which provides precise drug delivery for chronic therapy for severe spasticity. In addition to the implanted pump, the SynchroMed II infusion system uses a catheter to deliver programmed amounts of Lioresal® Intrathecal (baclofen injection) (a muscle relaxant and antispasticity agent) directly to the intrathecal space and cerebrospinal fluid. The pump and catheter are implanted under the skin.

F.I.R.S.TTM technology platform

image66

  BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.

Wed July 31, 2019 7:09 AM|PR Newswire|About: PFE 


 LUND, Sweden, July 31, 2019 /PRNewswire/ -- BioInvent International AB (BOVNF) ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. (PFE) ("Pfizer") (NYSE: PFE) 


 https://www.prnewswire.com/news-releases/bioinvent-announces-selection-of-first-target-discovered-by-bioinvents-proprietary-firsttm-technology-platform-under-collaboration-with-pfizer-inc-300893953.html 

Pipeline Bioinvent creates value by developing a risk-balanced portfolio of innovative oncology projects

Seeking biotech alpha July 2019 & October 2018 insight

EYLEA® (aflibercept)

image67

 EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial

Thu October 25, 2018 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/

EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye.

Ruxolitinib (Jakafi®)

image68

 FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease

Thu October 25, 2018 7:30 AM|Business Wire|About: INCY

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (INCY)

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also used to treat certain types of myelofibrosis.

Islatravir (MK-8591)

image69

 Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019

Wed July 24, 2019 11:00 AM|Business Wire|About: MRK

New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg)

Company Plans to Initiate Phase 3 Trials

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 July 24, 2019 11:00 AM Eastern Daylight Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK

XOFLUZA ™ (BALOXAVIR MARBOXIL)

image70

 

Wednesday, Oct 24, 2018

Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza

First and only single-dose oral medicine approved to treat the flu 
XOFLUZA significantly reduced the duration of flu symptoms compared to placebo
First novel proposed mechanism of action to treat the flu in nearly 20 years

South San Francisco, CA -- October 24, 2018 --

XOFLUZA is a prescription medicine used to treat the flu (influenza) in people 12 years of age and older who have had flu symptoms for no more than 48 hours.

seeking biotech alpha July 2019 & October 2018 insight

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib)

image73

 Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma

Thu October 18, 2018 6:57 AM|Business Wire|About: MRK 

KEYTRUDA is not chemotherapy or radiation therapy—it is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work.

Respiratory and Herpes Antiviral

image74

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Fri July 19, 2019 8:30 AM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis July 19, 2019 08:30 AM Eastern Daylight Time FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD

vedolizumab

Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

Mon July 22, 2019 1:00 AM|Business Wire|About: TAK

Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA)

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) (“Takeda”)  

Entyvio (vedolizumab) is indicated for adult patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) who have had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids, or who have had an inadequate response with, lost response to, or were intolerant to an immunomodulator or a tumor necrosis factor (TNF) blocker.1

Alzheimer’s Disease

image75

 Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Thu October 18, 2018 7:30 AM|GlobeNewswire|About: BIIB 

View BIOGEN full pipeline

ZERBAXA® 3g Dose (ceftolozane and tazobactam)

image76

 Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)

Mon July 29, 2019 4:05 PM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

ZERBAXA is indicated for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms: Enterobacter

seeking biotech alpha July 2019 & October 2018 insight

Tamiflu®

image78

Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care

Tue July 23, 2019 1:00 AM|GlobeNewswire|About: SNY

 Sanofi (SNY) signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care

PARIS – July 23, 2019 – Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu® for the prevention and treatment of influenza or flu in the US. 

Tamiflu is a prescription medicine used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days. Tamiflu can also reduce the chance of getting the flu in people 1 year and older.

JNJ to open JPOD hub at UPenn’s Pennovation Center in Philadelphia

image80

 The University of Pennsylvania Announces Agreement with Johnson & Johnson Innovation to Launch JPOD @ Philadelphia

 

Pennovation Media Contact: Jennifer Rizzi, Director, Communications, Facilities & Real Estate Services, 215.573.6107, rizzi@upenn.edu

July 18, 2018

University of Pennsylvania announces agreement with Johnson & Johnson Innovation to launch JPOD @ Philadelphia Jennifer Rizzi Writer DATE July 18, 2018 - target opening Nov. 1, 2018 at the university’s Pennovation Center in Philadelphia

Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF)

image81

 Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Tue October 30, 2018 6:36 AM|Business Wire|About: GILD 

 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)  

BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen for ≥3 months with no history of treatment failure and no known resistance to any component of BIKTARVY.

ALKS 5461 (buprenorphine/samidorphan)

image82

 Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry

 DUBLIN, Oct. 29, 2018 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS)  

Mon October 29, 2018 1:13 PM|PR Newswire|About: ALKS 

ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies -- -- New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 -- DUBLIN, Oct. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS)

OTEZLA® (apremilast)

image83

 FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Fri July 19, 2019 1:59 PM|Business Wire|About: CELG

OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study

With this third indication in the U.S., OTEZLA is the first and only treatment approved for oral ulcers associated with Behçet’s Disease

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG)

Otezla® (apremilast) is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis.

seeking biotech alpha July 2019 & October 2018 insight

Bimatoprost Sustained-Release (SR)

image86

U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension

Wed July 17, 2019 7:30 AM|PR Newswire|About: AGN

-- Allergan continues advancement in eye care innovation, developing specialized treatments for patients --

PR Newswire

DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (AGN)


U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension -- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release -- -- Allergan continues advancement in eye care innovation, developing specialized treatments for patients --

Intuitive Surgical, Inc. (ISRG)

image87

 Oct. 18, 2018 4:18 PM ET|About: Intuitive Surgical, Inc. (ISRG)|By: , SA News Editor 

Intuitive Surgical (NASDAQ:ISRG) Q3 results ($M): Revenue: 920.9 (+14.0%); Instruments & accessories: 486.3 (+21.2%); Systems: 274.6 (+4.8%); Services: 160.0 (+10.7%).

Net income: 292.5 (-2.0%); non-GAAP net income: 337.0 (+3.7%); EPS: 2.45 (-4.3%); non-GAAP EPS: 2.83 (+1.8%).

da Vinci system shipments: 231 (+36.7%).

Fourth generation da Vinci® Surgical Systems continue to advance Minimally Invasive Surgery (MIS) across a wide spectrum of surgical procedures.1 Flexible configurations, upgradable architecture and a consistent interface distinguish our family of da Vinci systems. Standardization of instruments and components can help manage inventory and improve overall OR efficiency.

Temozolomide

image89

 BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress

Mon October 22, 2018 7:15 AM|GlobeNewswire|About: BGNE 

Temozolomide is used for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM), a type of brain tumor. Temozolomide belongs to a class of drugs known as alkylating agents, and is a “pro-drug,” which means it is converted into its cancer-fighting form once inside the body. Temozolomide works by stopping or slowing the growth of cancer cells.

seeking biotech alpha July 2019 & October 2018 insight

IMFINZI® (durvalumab)

image90

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer

Mon July 22, 2019 8:00 AM|Business Wire|About: AZN

IMFINZI is the only immunotherapy approved to treat patients in this curative-intent setting following chemoradiation therapy

WILMINGTON, Del.--(BUSINESS WIRE)--

IMFINZI® (durvalumab) is a prescription medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.

Upadacitinib (ABT-494)

image91

 AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

Tue October 23, 2018 9:00 AM|PR Newswire|About: ABBV 

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis and axial SpA.

EPIDYOLEX™ (cannabidiol oral solution)

image93

 GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

Fri July 26, 2019 6:37 AM|GlobeNewswire|About: GWPH

If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy

GW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis


LONDON and CARLSBAD, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GWPRF) (Nasdaq: GWPH)

EPIDIOLEX is a prescription medicine that is used to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.

RUXIENCE™ (RITUXIMAB-PVVR)

image94

 FDA APPROVES PFIZER’S BIOSIMILAR, RUXIENCE™ (RITUXIMAB-PVVR), FOR CERTAIN CANCERS AND AUTOIMMUNE CONDITIONS

Tuesday, July 23, 2019 - 1:48pmEDT

Pfizer Inc. (NYSE:PFE) t

RUXIENCE™ (RITUXIMAB-PVVR)

Medtronic Partners with Viz.ai

image95

Medtronic Partners with Viz.ai to Accelerate Adoption of New Artificial Intelligence Software in U.S. Stroke Centers

July 22, 2019 | About: MDT +0% 


Technology Has the Potential to Save Crucial Time and Increase Access to Lifesaving Stroke Treatments

DUBLIN and SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (:MDT)


 http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2404287 

LVO Stroke Management

seeking biotech alpha July 2919 & October 2018 insight

ALUNBRIG® (brigatinib)

image97

 Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

Fri October 19, 2018 8:00 AM|Business Wire|About: TKPYY 

ALUNBRIG is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC): that has a certain type of abnormal anaplastic lymphoma kinase (ALK) gene, and that has spread to other parts of your body, and who have taken the medicine crizotinib, but their NSCLC worsened or they cannot tolerate taking crizotinib

Dengvaxia

 

Sanofi receives positive CHMP opinion for dengue vaccine

Paris, France - October 19, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi's dengue vaccine, recommending its approval in Europe.  

Dengvaxia® (also referred to as CYD-TDV), developed by Sanofi Pasteur, is a live recombinant tetravalent dengue vaccine, based on the yellow fever 17D vaccine strain, given as a 3-dose series with 6 months between each dose.

VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

image100

Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis

Mon July 22, 2019 8:00 AM|Business Wire|About: VRTX

-Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX


 https://www.businesswire.com/news/home/20190722005202/en/ 

SYMDEKO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO.

seeking biotech alpha October 2018 insight

XIFAXAN® (rifaximin)

image101

 Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

Mon October 29, 2018 7:00 AM|PR Newswire|About: BHC

Companies Announce Resolution of Outstanding Arbitration

BRIDGEWATER, N.J., Oct. 29, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Inc. ("Salix")

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease OCTOBER 29, 2018 Companies Announce Resolution of Outstanding Arbitration BRIDGEWATER, N.J., Oct. 29, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Inc. ("Salix")

tropifexor

image102

 Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH

Mon October 29, 2018 2:15 AM|Business Wire|About: NVS, PFE 

 Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, Phase 1) and a Ketohexokinase (KHK) Inhibitor (PF-06835919, Phase 2), together with Novartis’s tropifexor, a non-bile acid, Farnesoid X receptor (FXR) agonist. 

Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease October 29, 2018 02:15 AM EDT

ActoBiotics® Lactococcus lactis

image103

 ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

Mon October 29, 2018 7:30 AM|PR Newswire|About: XONPR Newswire

GHENT, Belgium, Oct. 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) 

GHENT, Belgium, Oct. 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes A unique approach to induce immune tolerance using specifically targeted and designed ActoBiotics® Lactococcus lactis engineered to express therapeutic agents.

GalXC™ RNAi technology

image104

 Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

Mon October 29, 2018 6:00 AM|PR Newswire|About: DRNA, LLY 

 INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Dicerna Pharmaceuticals (DRNA)  

Lilly and Dicerna Announce RNAi Licensing and Research Collaboration

Thermo Fisher Scientific Inc. TMO

image106

 Thermo Fisher Scientific Opens Newly Expanded Facility in Frederick, Md.

Mon October 29, 2018 8:30 AM|PR Newswire|About: TMOPR Newswire

FREDERICK, Md., Oct. 29, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc., 

Thermo Fisher Scientific Opens Newly Expanded Facility in Frederick, Md. FREDERICK, Md., Oct. 29, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc.,

seeking biotech alpha July 2019 & October 2018 insight

faricimab (RG7716)

image107

 New STAIRWAY Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)

 

South San Francisco, CA -- October 27, 2018 --

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 RHHBY 

Genentech has multiple products on the market for serious or life-threatening medical conditions.

Repatha® (Evolocumab)

image108

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

 THOUSAND OAKS, Calif., Oct. 26, 2018

 /PRNewswire/ -- Amgen (NASDAQ:AMGN) 

 Repatha Results in Consistent 

Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function
Results Presented at American Society of Nephrology Kidney Week 2018

 AMGN  

Repatha® is a groundbreaking treatment that reduces your risk of having a heart attack or stroke for real. Repatha® is proven to: Dramatically lower your LDL bad cholesterol Significantly drop your risk of having a devastating heart attack or stroke Reduce the need for a stent or open-heart bypass surgery

Nubeqa® (darolutamide)

image109

  FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer

- Nubeqa was approved under the FDA's Priority Review designation; approval granted three months ahead of target FDA action date

- Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of Nubeqa plus androgen deprivation therapy (ADT) compared to placebo plus ADT(1)

A prescription medicine used to treat men with prostate cancer that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone, such as androgen deprivation therapy (ADT).

brolucizumab (RTH258)

image110

Novartis is going after a $5 billion market with a new treatment for vision loss. That's a big threat to Regeneron

Lydia Ramsey 20h - Business Insider
 (NVS)

New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval - Basel, April 30, 2018

ZYTIGA® (abiraterone acetate)

image111

 Court Issues Ruling in ZYTIGA® Patent Infringement Litigation

Fri October 26, 2018 5:48 PM|PR Newswire|About: JNJ

NEW BRUNSWICK, N.J., Oct. 26, 2018 /PRNewswire

ZYTIGA® (abiraterone acetate) is a prescription medicine that is used along with prednisone. ZYTIGA® is used to treat men with prostate cancer that has spread to other parts of the body.

capmatinib

image112

 Novartis' capmatinib shows positive effect in mid-stage lung cancer study

Oct. 22, 2018 10:37 AM ET|By: , SA News Editor 

 Novartis in-licensed capmatinib, an oral MET inhibitor, from Incyte (INCY) in 2009. 

Clinical Trials Using Capmatinib

seeking biotech alpha July 2019 & October 2018 insight

diroximel fumarate

image113

 Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

Tue July 30, 2019 7:30 AM|PR Newswire|About: ALKS, BIIB 


 PR Newswire

DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) and Biogen Inc. (BIIB


ALKERMES AND BIOGEN ANNOUNCE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF DIROXIMEL FUMARATE NEW DRUG APPLICATION FOR MULTIPLE SCLEROSIS February 25, 2019 at 7:30 AM EST DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB)

Aducanumab (BIIB037)

image114

 Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

Fri October 26, 2018 9:15 AM|GlobeNewswire|About: BIIB 

Aducanumab (BIIB037) is being developed by Biogen as a possible Alzheimer’s disease therapy. Alzheimer’s News Today

Oral Semaglutide

image115

 Novo Nordisk's oral semaglutide successful in late-state T2D study

Oct. 26, 2018 9:14 AM ET|About: Novo Nordisk A/S (NVO)|By: , SA News Editor 

Novo Nordisk Pioneer 8 Trial Of Oral Semaglutide Achieved Primary Objective by Reuters Friday, 26 October 2018 12:57 GMT

BioMarin Pharmaceutica (BMRN)

image116

 BioMarin Pharma Q3 top line up 17%; Vimizim sales up 37%

Oct. 25, 2018 4:27 PM ET|About: BioMarin Pharmaceutica... (BMRN)|By: , SA News Editor 

BioMarin Pharmaceutical (NASDAQ:BMRN) Q3 results ($M): Revenues: 391.7 (+17.2%); Product sales: 386.3 (+29.3%).

VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Regeneron Pharmaceuticals, Inc. (REGN)

image117

 October 26, 2018 at 7:00 AM EDT REGENERON RANKED #1 BIOPHARMA EMPLOYER FOR SIXTH TIME BY SCIENCE MAGAZINE

TARRYTOWN, N.Y., Oct. 26, 2018 /PRNewswire/ --

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN 

Regeneron Pharmaceuticals, Inc. (REGN

Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries.

TLR7 agonists vesatolimod (GS-9620) and GS-986

image118

 July 23, 2019 

Gilead Announces Latest Data in Ongoing HIV Cure Research Program

New Studies Evaluate Agents with Potential Role in Eliminating HIV Viral Reservoir

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 23, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) 

Gilead Announces Latest Data in Ongoing HIV Cure Research Program July 23, 2019, 4:00 PM EDT

seeking biotech alpha July 2019 & October 2018 insight

REVLIMID® (lenalidomide)

image119

 REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma

Tue October 23, 2018 4:30 PM|Business Wire|About: CELG

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG)

REVLIMID® (lenalidomide) is a prescription medicine, used to treat people with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells).

Verzenio® (abemaciclib)

image120

 Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2

07/30/2019 

 Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival
MONARCH 2 was a Phase 3 study including both pre/peri- and postmenopausal women whose cancer progressed following endocrine therapy

INDIANAPOLIS, July 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)

Verzenio is a prescription medicine used to treat a type of breast cancer. It is a medicine you can take if: You have a type of breast cancer called HR+/HER2− (hormone receptor positive/human epidermal growth factor receptor 2 negative) and the cancer has spread to other parts of the body (metastasized) Verzenio is given in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, in combination with fulvestrant in women whose disease has progressed after hormonal therapy, or alone in women whose disease has progressed after hormone therapy and prior chemotherapy

Vedolizumab

image122

 Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

October 22, 2018 Osaka, Japan 

Vedolizumab (trade name Entyvio) is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease.

INGREZZA® (valbenazine)

image123

 Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress

Tue October 23, 2018 4:01 PM|PR Newswire|About: NBIXPR Newswire

SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

seeking biotech alpha July 2019 & October 2018 insight

dapirolizumab pegol (DZP)

image125

 BRUSSELS, Belgium and CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Today UCB (Euronext Brussels: UCB) and Biogen Inc (BIIB). (Nasdaq: BIIB) announced top-line results from a Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol (DZP), an anti-CD40L pegylated Fab, in adults with moderately-to-severely active systemic lupus erythematosus (SLE) despite receiving standard-of-care treatment such as corticosteroids, anti-malarials and non-biological immunosuppressants. 

UCB AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM A PHASE 2B STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS October 23, 2018 at 1:00 AM EDT BRUSSELS, Belgium and CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE)

Upadacitinib (ABT-494)

image127

 Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis

Mon October 22, 2018 6:01 PM|PR Newswire|About: ABBV 

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis and axial SpA.

BAQSIMI™ (glucagon) Nasal Powder 3 mg

image128

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA

Wed July 24, 2019 11:19 PM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, July 24, 2019 /PRNewswire/ -

FDA NEWS RELEASE July 24, 2019 FDA approves first treatment for severe hypoglycemia that can be administered without an injection

Johnson & Johnson (JNJ)

image130

 J&J makes $2.1B offer to buy out Ci:z

Oct. 23, 2018 4:58 AM ET|By: , SA News Editor  

 JNJ  

Ci:z Holdings Co., Ltd. Conception, development, manufacture and sale of cosmetics, health food, beauty care devices and other products

seeking biotech alpha October 2018 insight

IBRANCE® (palbociclib)

image131

 Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Sat October 20, 2018 10:30 AM|Business Wire|About: PFE 

IBRANCE® (palbociclib) is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.

Entrectinib

image132

 Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors

Sun October 21, 2018 5:00 AM|Business Wire|About: RHHBY 

Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors

DUPIXENT®

image134

 Oct. 20, 2018 5:31 PM ET|About: Regeneron Pharmaceutic... (REGN)|By: , SA News Editor 

The FDA approves Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi's (NYSE:SNY) DUPIXENT (dupilumab) as add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

DUPIXENT is a prescription medicine used to treat adult patients with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids.

Larotrectinib

image135

 Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types

Sun October 21, 2018 5:12 AM|PR Newswire|About: LOXO 

Our lead therapy in clinical development, larotrectinib, is an oral and selective inhibitor of tropomyosin receptor kinases (TRK), a family of signaling proteins that play an important role in cellular communication and tumor growth.

TEVA

image136

 Sun October 21, 2018 8:23 AM|Business Wire|About: TEVA

PARSIPPANY, N.J.--(BUSINESS WIRE)-

 Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel

Teva Specialty Pipeline -Pipeline is current as of April 2018